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Abstract

Due to elevated readmission costs, the Affordable Care Act established the Hospital
Readmission Reduction Program in 2012 to curb the 30-day readmission rates. COPD and
schizophrenia are two very expensive diseases, COPD national medical costs is projected to be
$49.0 billion in 2020; the cost of schizophrenia was 155.7 billion in 2013. The main objective of
this study was to determine if schizophrenia is a significant predictor of 30-day readmission
following hospitalization for acute exacerbation of COPD after adjusting for age, gender,
anxiety, smoking status, T2DM, chronic ischemic heart disease, and GERD. Methods: A
retrospective cohort design was used to request data from the South Carolina RFA. Data were
from January 1, 1996 to September 30, 2015 with primary or secondary diagnosis of ICD 9
491.21 or 491.22. The RFA created a unique identifier for each patient. Schizophrenia was
defined as and ICD 9 diagnostic code of 295.XX. Calculations were initially made in R, then in
SPSS. Results: Unadjusted and adjusted analyses per the robust GEE matrix revealed that
schizophrenia was not a significant indicator for 30-day COPD readmission (p = 0.105 and 0.054
respectively). However, GEE model-based method indicated that schizophrenia was a significant
predictor of 30-day readmission for COPD in both the unadjusted analysis (p = 0.019) and the
adjusted analysis (p = 0.002). Conclusion: Although not quite statistically significant per the
more reliable robust matrix, the results raise the possibility that schizophrenia could be a
predictor of readmission. Further studies using a prospective approach are recommended.
Keywords: COPD, schizophrenia, 30-day readmission.
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CHAPTER 1
Description of the Problem
Chronic obstructive pulmonary disease (COPD) is a progressive disorder characterized
by airflow limitation not fully reversible, caused by chronic inflammation of the airways and
lung parenchyma (GOLD, 2018, Sutherland & Cherniack, 2005). Individuals suffering from
COPD also have some substantial extrapulmonary effects, and important comorbidities that may
contribute to the severity of the disease (Rabe et al., 2007). About 90% of COPD cases are
caused by cigarette smoking; other risk factors include advanced age and genetic factors such as
α-1 antitrypsin deficiency (Epocrates, 2016). COPD is an expensive disease responsible for
roughly 750,000 hospitalizations in the US, and the cost associated with the care of patients with
COPD was estimated to approximated 24 billion dollars in 1993 (Sullivan & Ramsey, 2000). In
2008, the combined cost of COPD and asthma was 68 billion, including 53.7 billion in direct
cost; mortality rate was 14.3% (NHLBI, 2012). There were 7.3 million emergency department
visits (CDC, 2015).National medical costs are projected to increase from $32.1 billion in 2010 to
$49.0 billion in 2020 (Ford, Murphy, Khavjou, Giles, Holt, & Croft, 2015). COPD is also a lifethreatening condition; according to Barnes (2000), the World Health Organization predicted that
worldwide, COPD would be the third leading cause of mortality and the fifth leading cause of
disability by 2020.
Schizophrenia is a scarce; but very serious mental disorder affecting more males than
females (WHO, 2016). Worldwide in 2009, about one percent of the population was diagnosed
with schizophrenia, and approximately 1.2% of Americans (3.2 million) had the disorder
(Nemade & Dombeck, 2009). Still in 2009, about 1.5 million people were diagnosed with
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schizophrenia worldwide, translating to about 100,000 Americans diagnosed; in other words, 7.2
people per 1,000 or about 21,000 people within a city of 3 million were likely to be suffering
from schizophrenia (Nemade & Dombeck, 2009). Despite its scarcity, schizophrenia is affecting
more and more people and the statistics are still alarming; in 2016, more than 21 million people
worldwide suffer from it; 12 million males and 9 million females (WHO, 2016). In 2013,
schizophrenia was ranked as the 11th leading cause of disability worldwide (Global Burden of
Disease Study 2013 Collaborators, 2015).
Most people with schizophrenia are mentally disabled, and their disability can in turn
affect their educational and occupational performance (WHO, 2016). Schizophrenia is often
associated with stigma, discrimination and violation of human rights of people who have it
(WHO, 2016). Additionally, it is very costly for families and society. The number of emergency
departments (ED) visits related to schizophrenia was estimated to 382,000 from 2009 to 2011. Of
these visits, 32.7% resulted in a hospital admission, a higher percentage compared with ED visits
not related to schizophrenia (10.3%). Similarly, 16.7% of ED visits related to schizophrenia
resulted in a transfer to a psychiatric hospital, versus 0.7% of the ED visits not related to
schizophrenia (CDC, 2015b). In 2002, the overall cost of schizophrenia was estimated to be
$62.7 billion, with $22.7 billion in excess direct healthcare cost in the following categories: $7.0
billion outpatient, $5.0 billion drugs, $2.8 billion inpatient, and $8.0 billion long-term care (Wu
et al., 2005). Cloutier et al. (2016) reported that the cost associated with schizophrenia in 2013
was estimated at $155.7 billion 2013 and included excess direct health care costs of $37.7 billion
(24%), direct non–health care costs of $9.3 billion (6%), and indirect costs of $117.3 billion
(76%) compared to individuals without schizophrenia. The majority of expenses were associated
with unemployment (38%), productivity loss due to caregiving (34%), and direct health care
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costs (24%). These elevated costs do not unfortunately translate in decreased mortality; in fact,
people with schizophrenia are still 2 to 2.5 times more likely to die prematurely than the general
population, due to physical illnesses such as cardiovascular, metabolic and infectious diseases
(WHO, 2016).
The National Institute for Mental Health (NIMH, n.d.) defines schizophrenia as a chronic,
severe and debilitating mental disorder that alters thoughts, behavior, feelings and perception in
people affected by it. Onset of schizophrenic symptoms is usually in early adulthood, although
there are rare pediatric schizophrenias. Symptoms are classified as positive, negative or
cognitive. Positive symptoms include delusion, hallucinations, thoughts disorders, and catatonia.
Negative symptoms are self-neglect, demotivation, affective flattening, anhedonia, and
impoverished or disorganized speech and language or alogia. Cognitive symptoms include
attention deficit, poor executive functioning and poor working memory. It is thought that their
poor working memory is due to a specific deficit in their prefrontal cortex function, as evidenced
by their poor performance on continuous Performance Test measured on magnetic resonance
imaging (Barch, Carter, Braver, Sabb, MacDonald III, Noll, & Cohen, (2001). Diagnosis of
schizophrenia is made on the basis of co-occurrence of at least two of the listed symptoms
occurring for a significant period of at least one month associated with ongoing problems for at
least 6 months; at least one of the symptoms must be a positive symptom (APA, 2013).
Individuals with schizophrenia are likely to suffer multiple co-morbid conditions that
could potentially lead to hospitalizations. Olfson, Gerhard, Huang, Crystal, & Stroup (2015)
sought to describe the overall cause of mortality and the specific mortality rates and standardized
mortality ratios (SMRs) for adults with schizophrenia in the United States. They calculated
mortality rates per 100,000 person-years and the mean years of potential life lost per death and
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found that adults with schizophrenia were more than 3.5 times (all-cause SMR, 3.7; 95% CI, 3.73.7) as likely to die in the follow-up period as were adults in the general population.
Problem Statement or Purpose and Development of PICO Question.
COPD is a preventable and manageable chronic condition; but individuals with
schizophrenia have the tendency not to adhere to their prescribed regimen (Lacro, Dunn, Dolder,
Leckband, & Jeste, 2002). Cahoon, Mcginty, Ford, & Daumit (2013) sought to determine if
individuals with schizophrenia were at higher risk for ambulatory care sensitive (ACS)
hospitalizations due to the nature of their disease, barriers to high quality primary care, lack of
social support, and fragmentation of healthcare delivery services. Overall, acute, and chronic
ACS hospitalizations were higher for admissions with secondary diagnosis of schizophrenia
compared to those without (OR 1.34; 95% CI: 1.31, 1.38). Unadjusted ORs of the majority of
chronic ACS conditions measured, including congestive heart disease (CHF), COPD, asthma,
diabetes mellitus (DM), long and short-term complications, and uncontrolled diabetes were
higher for hospitalizations with schizophrenia, versus without secondary diagnosis of
schizophrenia.
Ho, Tsai, Ruan, Huang, & Lai (2014) sought to determine in-hospital mortality and oneyear mortality for patients with COPD and their predictors in patients hospitalized for first-ever
disease exacerbations. Older and hospitalized COPD patients had more comorbidities such as
congestive heart failure (CHF), malignancies or stroke, and were more likely to die (OR: 1.08
per point; 95% CI: 1.01–1.15). A greater number of COPD survivors had hyperlipidemia.
Angiotensin II receptor blockers (ARBs), beta blockers and statins were more frequently
prescribed to patients who survived. Also, hospital length of stay was longer for non-survivors
(hazard ratio 1.01 per day; 95% CI: 1.01–1.01), they experienced more cardiac events, and they
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were more likely to be admitted to ICU for mechanical ventilation (HR: 1.33; 95% CI: 1.03–
1.73). As far as one-year outcome was concerned, concomitant liver cirrhosis and malignancy,
and length of stay and ICU admissions during the index hospitalization were significant
independent predictors of mortality.
Additionally, Guerrero et al. (2016) found that 20% of COPD patients were readmitted
for acute exacerbation of COPD (AECOPD) within 30-days of discharge. They found that 30day readmission for AECOPD correlated with increasing long-term mortality risk; more
precisely, the absolute increase in mortality rate was 4% at 30 days, 17% at 6 months, 19% at
one year, and 24% at 3 years. Guerrero et al. also found that 30-day readmission was an
independent risk factor for mortality at one year (HR 2.48; 95% CI, 1.10-5.59).
Furthermore, previous hospital admission, increased PaCO2, low forced expiratory
volume in one second (FEV1), dyspnea, oral corticosteroids, long term use of oxygen therapy,
poor health related quality of life or inability to perform activities of daily living, and absence of
routine physical examination by a primary care provider were found to be significant risk factors
for admissions and readmissions to the hospital of AECOPD (Bahadori & Fitzgerald, 2007).
Conversely, regular physical activity and higher quality of life were associated with reduced
admission risk at a statistically significant level. The Lung Health Study also demonstrated that
exacerbations contribute to decline in FEV1 (Donaldson & Wedzicha, 2006)).
In regard to schizophrenia, Jørgensen (2017) examined the association between
schizophrenia and the quality and predictors of care for diabetes, heart failure and COPD in
Danish populations, as well as the clinical outcomes of heart failure and COPD among patients
with schizophrenia. She found that COPD patients with schizophrenia had a lower probability of
meeting certain process-performance measures for COPD, CHF and diabetes mellitus.
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Additionally, patients with schizophrenia were more likely to die after an admission for
AECOPD.
Furthermore, a comprehensive database search from January 1990 to June 2014 indicated
that a number of studies supported the hypothesis that patients with mental disorders are more
likely to be readmitted if they have co-occurring medical conditions (Šprah, Dernovšek,
Wahlbeck, & Haaramo, 2017). In fact, co-occurring physical and mental disorders can worsen a
patient’s course of illness leading to hospital readmission not related to their psychiatric
condition. Medical diagnoses such as chronic lung diseases, hepatitis C virus infection, and
hypertension were associated with readmission for substance abuse disorder and schizophrenia.
Due to elevated costs associated with readmissions, the Affordable Care Act (ACA)
established the Hospital Readmission Reduction Program (HRRP) in 2012 with the aim to curb
the 30-day readmission rate. Under the HRRP, hospitals are penalized if their 30-day
readmission rates are greater than expected for acute myocardial infarction, CHF, pneumonia,
elective total hip arthroplasty, total knee arthroplasty, and acute exacerbation of COPD
(McIlvennan, Eapen, & Allen, 2015). Additionally, institutions such as the Veterans Health
Administration (VHA) uses the 30-day readmission rate as a SAIL (Strategic Analytics for
Improvement and Learning) measure. The SAIL combines private sector key metrics and metrics
specific to the VHA to address access to care, quality of mental health care, employee perception
about the organization, nursing turnover and efficiency (U.S. Department of Veterans Affairs,
2016).
The studies summarized above are evidence of an existing link between mental illnesses
such as schizophrenia and increased mortality, hospitalization and rehospitalization odds.
Research to examine if the coexistence of schizophrenia would increase 30 day-readmission rates
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of South Carolinians with COPD is rather slim or nonexistent. If the diagnosis of schizophrenia
correlates with greater hospitalization and readmission rates as seen in the literature, hospitals in
South Carolina can scheme specific medical and social services for this fringe of vulnerable
population.
Based on the current research on the coexistence of schizophrenia and COPD as it relates
to hospital readmission, the principal key objectives of this research study is to determine if
schizophrenia is a significant predictor for 30-day COPD readmission after adjusting for the
other covariates age, gender, anxiety, smoking status, T2DM, chronic ischemic heart disease, and
GERD). A secondary objective is to suggest lifestyle approaches to manage both COPD and
schizophrenia. This approach would have a significant impact given that neuroleptic used for
schizophrenia management are highly associated with the development of type 2 diabetes
mellitus (Bobo et al., 2013). The PICO question for this research study is as follows: “In the
hospitalized South Carolinians with COPD (P), how does having schizophrenia (I) compared to
not having schizophrenia (C) influence the 30-day readmission rate (O)? The project is an
investigational project which aims to improve the quality of care provided to South Carolinians
with schizoaffective disorders/schizophrenia and COPD. If schizophrenia is a significant
predictor for COPD readmission, since schizoaffective disorders are a worldwide problem,
healthcare providers could benefit from the results and suggestions of the research findings.
Theoretical Framework
The uncertainty in illness theory (UIT), the reconceptualized uncertainty in illness theory
(RUIT), and the CREATION Health theory will be used as framework for this project. Mishel
(2014) developed the UIT in 1988 to address “uncertainty during the diagnosis and treatment
phases of an illness or an illness with a determined downward trajectory” (p. 53). She defined
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uncertainty as “the inability to determine the meaning of illness-related events.” Mishel
subsequently developed the RUIT “to address the experience of living continuous uncertainty in
either a chronic illness requiring ongoing management or an illness with a possibility of
recurrence” (p. 53). UIT is centered around three principal themes: antecedents of uncertainty,
appraisal of uncertainty, and coping with uncertainty without a desired outcome of returning to
the previous level of adaptation or functioning. Mishel added the concepts of self-organization
and probabilistic thinking to create the RUIT with the desired outcome of growth to a new value
system (p. 53). Due to its irreversible nature, COPD can trigger lots of anxiety and uncertainty in
people affected by this disease. COPD and schizophrenia both have uncertain trajectories; nurse
practitioners can help patients who have these conditions by implementing nursing actions to
help them prevent, predict and manage acute episodes. In conclusion, healthcare providers can
use UIT and RUIT in various ways and settings not only to predict and manage COPD and
schizophrenia exacerbations, but also to educate families and patients on the trajectories of these
diseases.
The approach to this study would have a unique conceptualization due to the introduction
of the CREATION Health (Edgerton, 2014) model as a novel framework to manage both COPD
and schizophrenia. The CREATION Health (Edgerton, 2014) model would simultaneously shed
light on the etiology of some symptoms and provide long term solutions to symptoms
management. It would be practically impossible to manage the schizophrenic patient with COPD
outside of his/her psychotic disorder. Although the etiology of schizophrenia is not well known,
it is now known that genetic, perinatal and environmental factors as well as cannabis play an
important part in psychosis/schizophrenia development (Frankenburg, 2017). Some epigenetic
studies have demonstrated that methamphetamine that causes psychosis in humans alters DNA
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methylation as well as expression of genes in brain regions that are thought to be involved in
schizophrenia (Numachi et al. 2004). Schizophrenia treatment should no longer be limited to
pharmacological approaches; non-pharmacological management including psychosocial
interventions and nutrition have been proven to be effective in treating schizophrenia (ÁlvarezJiménez, Hetrick, González-Blanch, Gleeson, & McGorry, 2008). The CREATION Health
approach to lifestyle advocates that proper nutrition preserves lung function and leads to healthy
brains. Individuals with healthy frontal lobe would make good choices and avoid cigarette
smoking, one of the primary causes of COPD. There is evidence that pulmonary rehabilitation
and regular physical activity -regardless of the level of physiologic decline- can improve the
quality of life (Seemungal, Hurst, & Wedzicha, 2009, p. 213). In fact, all the aspects of the
CREATION Health model are important in managing both COPD and schizoaffective disorders
(see Figure1). Controlling COPD symptoms, adopting healthy lifestyles and having proper
interpersonal relationships would improve the 30-day readmission rate of the schizophrenic
South Carolinians with COPD.
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CHAPTER 2
Literature Review
A review of literature related to chronic obstructive pulmonary disease (COPD),
schizophrenia, COPD and schizophrenia, as well as medical, pharmacological, and nonpharmacological management of COPD and schizophrenia was made. Resources used include
medical databases at the McKee Library and the Veterans Administration National Library, as
well as internet search in PubMed-NCBI, Google Scholar, and Open Access Journal Search
Engine.
COPD

In a retrospective population-based cohort, Ho, Tsai, Ruan, Huang, & Lai (2014) sought
to determine in-hospital mortality and one-year mortality for patients with COPD and their
predictors in patients hospitalized for first-ever disease exacerbations. Patients who were older
and hospitalized had more comorbidities such as congestive heart failure (CHF), malignancies,
stroke, were more likely to die (OR: 1.08 per point; 95% CI: 1.01–1.15) than survivors. A greater
number of survivors had hyperlipidemia. Hospital length of stay was longer for non-survivors
(HR 1.01 per day; 95% CI: 1.01–1.01), they experienced more cardiac events, and they were
more likely to be admitted to the ICU for mechanical ventilation (HR: 1.33; 95% CI: 1.03–1.73).
At one-year, concomitant liver cirrhosis, malignancy, length of stay and ICU admissions during
the index hospitalization were significant independent predictors of mortality.
Shams, Ajorlou, & Yang (2015) determined that various models intended to predict and
reduce hospital readmission rates were not accurate enough and did not incorporate timing of
readmission in their predictions. They developed a new readmission metric that can identify
potentially avoidable readmissions from all other types of readmissions. Shams et al. also

THE IMPACT OF SCHIZOPHRENIA

17

proposed a tree-based classification method to estimate the predicted probability of readmission
that can directly incorporate patient’s history of readmission and risk factors changes over time.
They applied their new readmission metric by retrospectively examining 7200 records
corresponding to 2985 different adult patients with principal (or secondary) discharge diagnoses
of heart failure (HF), acute myocardial infarction (AMI), pneumonia (PNA), and COPD in
veterans seeking care at various Veterans Administration (VA) hospitals in the state of Michigan
from 2011-2012. Their model was effective at predicting the reduction of 30-day avoidable
readmissions of patients with HF, AMI, PNA, and COPD. Their results showed increased
discrimination power compared to the literature (c-statistics > 80%) and good calibration.
However, Shams et al.’s study was limited to the state of Michigan (Veterans Integrated Service
Network [VISN] 11) comprising mostly male veterans. Furthermore, it did not include laboratory
results and vital signs which could also contribute to readmissions.
Schizophrenia
Individuals with schizophrenia are likely to suffer multiple co-morbid conditions that
could potentially lead to hospitalizations. Olfson, Gerhard, Huang, Crystal, & Stroup (2015)
sought to describe the overall cause of mortality and the specific mortality rates and standardized
mortality ratios (SMRs) for adults with schizophrenia in the United States. They used mortality
rates and mortality ratios standardized to the general population by age, sex, race/ethnicity, and
geographic region to characterize and stratify the burden and excess mortality from common
medical problems. They calculated mortality rates per 100,000 person-years and the mean year
of potential life lost per death. The cohort included 1,138,853 individuals, 4,807,121 years of
follow-up, and 74,003 deaths, of which 65,553 had a known cause. Adults with schizophrenia
were more than 3.5 times (all-cause SMR, 3.7; 95% CI, 3.7-3.7) as likely to die in the follow-up
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period as were adults in the general population. Cardiovascular disease had the highest mortality
rate (403.2 per 100,000 person-years) and an SMR of 3.6 (95% CI, 3.5-3.6). Among the six
selected cancers, lung cancer had the highest mortality rate (74.8 per 100,000 person-years) and
an SMR of 2.4 (95% CI, 2.4-2.5). SMRs were remarkably elevated for COPD (9.9; 95% CI, 9.610.2) and influenza pneumonia (7.0; 95% CI 6.7-7.4). Accidental deaths (119.7 per 100,000
person-years) were more than twice as many as suicidal deaths (52.0 per 100,000 person-years).
Non-suicidal substance-induced death, mostly from alcohol or other drugs, was also a leading
cause of death (92.2 per 100,000 person-years). Olfson et al. concluded that nicotine use and
other modifiable cardiovascular risks were the reasons for excess cardiovascular and respiratory
deaths in people with schizophrenia.
Davydow et al. (2016) found that in individuals with serious mental illnesses (SMIs) such
as schizophrenia or bipolar disorder were at increased risk for hospitalizations for ambulatory
care-sensitive conditions (ACSCs) and rehospitalization for the same or another ACSC within 30
days. Among individuals with ambulatory care-sensitive condition, serious mental illness was
associated with increased risk for hospitalizations for angina (Incidence rate ratios [IRR]: 1.14,
95% CI, 1.04–1.25), COPD/asthma exacerbation (IRR: 1.87; 95% CI, 1.74–2.00), congestive
heart failure exacerbation (IRR: 1.25; 95% CI, 1.16–1.35), and diabetes (IRR: 1.43; 95% CI,
1.31–1.57), appendiceal perforation (IRR: 1.49; 95% CI, 1.30–1.71), pneumonia (IRR: 1.72;
95% CI, 1.66–1.79), and urinary tract infection (IRR: 1.70; 95% CI, 1.62–1.78). SMI was also
associated with increased risk for rehospitalization within 30 days for the same (IRR: 1.28; 95%
CI, 1.18–1.40) or for another ACSC (IRR: 1.62; 95% CI, 1.49–1.76).
Burke, Donzé, & Schnipper (2013) aimed to determine the independent contribution of
psychiatric illness and substance abuse to all-cause and potentially avoidable 30-day
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readmissions in medical patients. They followed 6,987 patients discharged from a large teaching
hospital from July 1, 2009 to June 30, 2010, measured 30-day all-cause and potentially avoidable
readmissions (PAR). Burke et al. found that of the 6,987 discharged patients, 1260 were
readmitted within 30 days (18.0%); 388 readmissions were potentially avoidable (5.6%). Patients
treated for depression and schizophrenia while hospitalized were found to be at higher risk for
potentially avoidable 30-day readmissions; on the other hand, those prescribed more psychiatric
medications as outpatients are at increased risk for all-cause readmissions.
Mai, Holman, Sanfilippo, & Emery (2011) examined mental illness-related disparities in
potentially preventable hospitalizations (PPHs). They sought to answer the four specific
following questions: 1) do mental health clients (MHCs) have more PPHs than non-MHCs; 2)
which PPH category/medical condition has the highest relative risk; 3) do the associations vary
by category of mental disorders; and 4) what would be the potential savings in hospital
admissions if MHCs had received the ‘same’ quality of primary care as non-MHCs? They
discovered that PPHs accounted for more than ten percent of all hospital admissions in mental
health clients (MHCs). Diabetes and its complications, adverse drugs events, COPD, convulsions
and epilepsy, and congestive heart failure (CHF) were the common causes. Ali et al. also found
that compared with non-MHCs, MHCs with any mental disorders were more likely to experience
a PPH than non-MHCs (overall ARR 2.06, 95% CI 2.03-2.09). Furthermore, adjusted rate ratios
of potentially preventable hospitalizations were highest for convulsions and epilepsy, nutritional
deficiencies, COPD and adverse drugs events. The ARR of a PPH was highest in mental health
clients with alcohol/drug disorders, affective psychoses, other psychoses and schizophrenia.
Brown, Inskip, & Barraclough (2000) investigated the standardized mortality ratio (SMR)
and the reasons for excess mortality in a community cohort of 370 schizophrenic individuals
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aged 16-65. They followed the cohort for 13 years and found that the SMRs were 298 for all
causes of death, 232 for natural causes, and 1273 for unnatural deaths. These SMRs were
significantly higher than those to be expected in the general population: three-fold increase for
all causes of death, two-fold increase for natural cause mortality, and 12 times increase for
unnatural deaths. The SMRs for diseases of the circulatory, digestive, endocrine, nervous and
respiratory systems, suicide and undetermined health were also significantly higher than those to
be expected in the general population. Finally, fatal diseases from cigarette smoking were more
conspicuous than in the general population. Brown, Inskip, & Barraclough (2000) concluded that
since the mechanisms of excess schizophrenia-related mortality are known for the most part, thus
should be controlled with current guidelines. Of utmost importance, psychiatrists and mental
health providers should stay up-to-date with guidelines recommendations and be assertive in
addressing smoking, alcohol use, diet and other modifiable lifestyle factors.
Cahoon, Mcginty, Ford, & Daumit (2013) examined the association of schizophrenia
with acute and chronic ambulatory care sensitive (ACS) hospitalizations. They defined ACS as
hospitalizations potentially preventable by timely primary care. Cahoon et al. used the
Prevention Quality Indicators (PQIs) developed by the Agency for Healthcare Quality and
Research (AHRQ) to identify ACS hospitalizations and analyze hospital discharge data from the
Nationwide Inpatient Sample (NIS). They found that schizophrenia was associated with
increased odds of hospitalization for acute ACS conditions (OR = 1.34; 95% CI: 1.31, 1.38), as
well as for chronic ACS conditions (OR 1.04, 95% CI 1.01-1.06). Hospitalization for acute ACS
conditions were remarkable for COPD (OR 1.52, 95% CI 1.46-1.59), asthma (OR 1.14, 95% CI
1.08-1.20), diabetes mellitus short-term complications (OR 1.42, 95% CI 1.33-1.50), and
uncontrolled diabetes (OR 2.34, 95% CI 2.20-2.50). Nonetheless, schizophrenia was associated
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with decreased odds of hospitalization for congestive heart failure, diabetes mellitus long-term
complications, angina without procedure, and diabetes related lower- extremity amputations.
Schizophrenia was not associated with hospitalization for hypertension.
In a meta-analysis study intended to investigate factors influencing readmission in
depression or schizophrenia, Bridge & Barbe (2004) found five principal factors that seemed to
influence the risk of rehospitalization: (1) patient factors: sex, marital status, age, and involuntary
first admission; (2) clinical factors such as psychiatric diagnosis, global functioning, the degree
and type of symptoms; (3) comorbid psychiatric disorders, such as substance abuse disorders,
history of past psychiatric hospitalization; (4) number of previous admissions; and (5) a poor
discharge prognosis. Concomitantly, they found that strategies with great potential to reduce
hospital readmissions for depression and schizophrenia included: (1) Medication Event
Monitoring System to ensure medication adherence or compliance; (2) linkage with outpatient
care; (3) disease management programs; (4) psychoeducation, and (5) psychiatry advance
directives.
Using a framework of specific care recommendations, Tsan et al. (2012) sought to
determine whether there were particular types and patterns of routine outpatient care that were
associated with improved survival for male veterans aged 50 years and older, diagnosed with
schizophrenia seeking care from the VA. They identified three groups. First, the high-consistent
care group, the largest (n= 20,854), with an average of 5.4 types of care annually. This group
included veterans with the most comorbidities; the unadjusted mortality rate of 26%. Second, the
moderate-consistent care group averaged 3.8 types of care; the unadjusted mortality rate was
36% (n = 18,218). Third, the poor-decreasing care group averaged 1.9 types of care across all
years; this group comprised the oldest veterans (but with a wider variation in age, with SD = 10
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years); however, it had the least comorbidity. The unadjusted mortality rate was 31% (n =
10,101). In the multivariable adjusted model, the hazard ratio (HR) for the moderate-consistent
group indicated a 41% increase in the mortality rate (HR = 1.41, 95% CI 1.36 to 1.47) relative to
the high-consistent group. However, patients in the poor-decreasing group experienced a 6%
decrease in mortality rate (HR = 0.94; 95% CI 0.90 to 0.99) relative to the high-consistent group.
COPD and Schizophrenia
In a retrospective record linkage study, Hoang, Stewart, & Goldacre (2011) desired on
one hand to investigate whether the mortality gap had reduced from 1999 to 2006 between
people with schizophrenia or bipolar disorder and the general population; and on the other hand,
to describe the relative contribution from natural death and unnatural causes of death. They
calculated mortality in 3 broad age groups after hospital discharge as age and sex standardized
mortality ratios, comparing mortality in people with schizophrenia or bipolar disorder with
mortality in the general population of England. The age groups were: <45, 45-64, and 65-84.
Patients aged 85 and over were excluded from analysis due to their small numbers. Poisson test
was used to investigate whether there was a significant trend in standardized mortality ratio over
time. Hoang et al. made the following findings: (1) from 1999 to 2006, the mortality gap had
widened overtime, and standardized mortality ratios in the psychiatric cohorts were about double
the population average; (2) for people discharged with schizophrenia, the ratio was 1.6 (95%
confidence interval 1.5 to 1.8) in 1999 and 2.2 (2.0 to 2.4) in 2006 (P< 0.001 for trend); for
bipolar disorder, the ratios were higher for unnatural than for natural causes; they were 1.3 (1.1
to 1.6) in 1999 and 1.9 (1.6 to 2.2) in 2006 (P= 0.06 for trend). Nonetheless, about three quarters
of all deaths were certified as natural, and increases in ratios for natural causes, especially
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circulatory and respiratory diseases, were the main components of the increase in all-cause
mortality.
Strid, Christiansen, Olsen, & Qin (2014) examined the risk of suicide among patients
hospitalized with COPD and profiled differences according to sex, age, psychiatric history,
recency and frequency of COPD hospitalization. They studied 19,869 cases who died from
suicide between ages 40–95 years from the year 1981 through 2006 and 321,867 matched
controls randomly selected from a 25% representative sample of the national population. They
used conditional logistic regression to estimate the association between hospitalization for COPD
and risk for subsequent suicide. Wald test was used to test differences in OR estimates between
groups and to examine interactions between COPD and sex, age and previous psychiatric illness.
Strid et al. found that the majority of suicide cases were men (n=12 548; 63.2%) and aged 40 to
60 years (n=10 877; 54.7%). In the study population, 3% (n=592) of suicide cases had a history
of hospitalization for COPD by the date of suicide compared with 1% (n=3087) of population
controls. Overall, hospitalization for COPD increased suicide risk signiﬁcantly more in
individuals with no recorded history of psychiatric illness (OR 2.6, 95% CI 2.3 to 2.9) than it did
for individuals with a psychiatric history (OR 1.2, 95% CI 1.0 to 1.5) after having controlled for
the main effect of psychiatric illness and the effects of socioeconomic factors. Regardless of sex
and age, COPD was a signiﬁcant risk factor for suicide in people without a psychiatric history.
For individuals with a prior hospital contact because of psychiatric illness, the additional risk of
suicide associated with COPD remained highly signiﬁcant only in female participants and in
patients above 60 years.
Partti et al. (2015) sought to determine if the respiratory health of individuals with
psychosis is different than that of the general population. They designed a two-stage cluster
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quasi-experimental study comprising 8028 participants aged 30 or over 3637 men (45.3%) and
4391 women (54.7%) stratified to represent the Finland’s adult population. Among other
dependent variables, psychosis was identified by DSM-IV-TR; lung function was measured by
spirometry; asthma was diagnosed if participants reported being diagnosed by a physician and
was taking anti-asthmatic medication(s); COPD was diagnosed as such if the participants had
been admitted to a hospital with COPD or had a spirometry result indicative of COPD according
to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria; and smoking was
objectively quantified with serum cotinine (S-Cot) levels. The most striking results of this study
were: (1) self-reported daily smoking and heavy smoking were significantly more common in
participants with schizophrenia compared with participants without psychosis; (2) participants
with schizophrenia had significantly higher serum cotinine (S-Cot) levels compared with
participants without psychosis, even after adjusting for age and gender (b=127.6 ng/mL, 95% CI
31.4–223.9 ng/mL, P=0.009) in a linear regression model; (3) participants with schizophrenia as
well as those with other non-affective psychoses had statistically significantly lower FEV1 and
FVC values but a normal FEV1/FVC ratio compared with participants without psychosis,
suggesting a restrictive ventilatory pattern. Overall, participants with schizophrenia and other
non-affective psychosis had significantly lower lung function values compared with the general
population, and the association remained significant for schizophrenia after adjustment for
smoking and other potential confounders. Schizophrenia was associated with increased odds of
pneumonia (odds ratio (OR) = 4.9), COPD, (OR = 4.2), chronic bronchitis (OR=3.8), and with
high cotinine levels.
Copeland et al. (2007) wanted to determine the risk associated with schizophrenia for
common pulmonary illnesses (pneumonia and COPD) during the last year of veterans’ lives.
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From the VA electronic database, they identified 27,798 deceased veterans in 2002 and analyzed
four parameters: pulmonary disease diagnosed in the final year of life, pulmonary disease
diagnosed in the final hospitalization where death occurred, final-year diagnosis of pneumonia,
and final-year diagnosis of COPD. They found that among the deceased, 943 (3.4% of 27,798)
had schizophrenia, 3% were women, most were white (76%) or African–American (18%), and
average age at death was 72.4 years (SD 11.5). For the primary outcome in the multivariable
model, schizophrenia nearly doubled the odds of pulmonary disease in the last year of life
(OR=1.9, 95% CI 1.6–2.2), after controlling for covariable effects. Odds of pulmonary disorders
were also greater for patients engaged in outpatient care or diagnosed with tobacco dependence
or other mental illness and increased slightly with age and Charlson comorbidity score. Nonwhite race, female gender, never-married status, diagnosis with substance abuse disorders, and
having minimal hospital days in the last year of life were negatively associated with the
diagnoses of COPD or pneumonia. Copeland et al. concluded that VA inpatient decedents with
schizophrenia were at increased risk for pneumonia and COPD, independent of smoking
indicators.
Medical and Pharmacological management of COPD
Adamson, Burns, Camp, Sin, & van Eeden (2016) sought to determine the impact of an
individualized care package (CP) on early readmission rates following a hospital admission due
to acute exacerbation of COPD (AECOPD). They reviewed data of patients admitted for
AECOPD to two inner-city teaching hospitals. The control group consisted of 271 patients
whose index AECOPD occurred the year before the comprehensive program, and the
experimental group consisted of 191 patients who received the comprehensive care. The primary
outcome measure was the total number of readmissions in 30- and 90-day post index
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hospitalizations. Secondary outcome measures included the length of time between the index
admission and first readmission and all-cause mortality. The CP team comprised a nurse, a
respiratory therapist and a physiotherapist. This team enrolled patients during hospitalization;
upon discharge, the team made post discharge phone calls, home visits, ensured that patients
followed up with their primary care providers and had the community resources needed; the team
also identified and addressed individual risk factors. The Student’s t-test and Fisher’s exact test
were used to analyze the two groups. The analysis of variance test with a post hoc Tukey test and
the chi-square test were used for comparison between four groups. Length of time until first
readmission was evaluated using the Student’s t-test. All-cause mortality was assessed through
the Kaplan–Meier estimate, using the log-rank test to determine significance. Adamson et al.
found that the CP significantly reduced 90-day readmission rates in females (P=0.0205, corrected
for age, BMI, number of comorbidities, substance abuse, and mental illness) but not in males or
in the whole group (P > 0.05). The average times between index admission and first readmission
were not different between the two groups. Post hoc multivariate analysis showed that substance
abuse (P < 0.01) increased 30- and 90-day readmissions (corrected for age, sex, BMI, number of
comorbidities, and mental illness). The 90-day all-cause in-hospital mortality rates were
significantly less in the care package group (2.67% versus 7.97%, P=0.0268). Overall, CP for
patients admitted to the hospital for AECOPD did not reduce 30- and 90-day readmission rates
for both genders but did reduce their 90-day total mortality; nonetheless, it reduced 90-day
readmission rate in females.
In order to better understand the reasons why patients with COPD poorly adhere to their
medication regimen, Huetsch, Uman, Udris, & Au (2012) sought, on one hand, to identify the
characteristics of patients who adhere to their inhaled medications; and the other hand to assess
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whether adherence to one medication class was associated with the adherence to the other
medication classes in patients who have multiple inhalers. Study participants were 2,730 veterans
in VISN 20 selected from the VA electronic databases diagnosed with COPD by pulmonary
function testing between January 2003 and December 2007. Huetsch et al. used pharmacy
records to estimate adherence to inhaled corticosteroids (ICS), ipratropium bromide (IP), and
long-acting beta-agonists (LABA) over two consecutive six-month periods. Veterans were said
to be adherent if they had refilled their medications to have 80% of drug available over the time
period. Covariates were demographics, behavioral habits, COPD severity, and comorbidities.
The most remarkable findings were that: (1) adherence was poor, with 19.8 % adherent to ICS,
30.6 % adherent to LABA, and 25.6 % adherent to IP; (2) predictors of adherence to inhaled
therapies were inconsistent and dependent on the medication being examined; (3) in adjusted
analysis, being adherent to a medication at baseline was the strongest predictor of future
adherence to that same medication [(Odds ratio, 95 % confidence interval) ICS: 4.79 (3.22–
7.12); LABA: 6.60 (3.92–11.11); IP: 14.13 (10.00–19.97)], but did not reliably predict adherence
to other classes of medication. Additionally, Huetsch et al. found that: (1) gender, race, and
smoking status were not associated with medication adherence; (2) overall, there was no
association between medication adherence and the presence of particular comorbid conditions,
nor with the number of total drug classes that patients had received; (3) older age and fewer
missed clinic visits were associated with LABA adherence only; (4) a previous diagnosis of lung
cancer or asthma was associated with decreased adherence to LABA, while a diagnosis of acute
coronary syndrome or depression was associated with decreased adherence to IP.
Moy et al. (2016) examined the effects of a 12-month Internet-mediated, pedometerbased walking intervention called Taking Healthy Steps by randomizing 239 veterans with
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COPD in a 2:1 ratio to the intervention or wait-list control. The primary outcome was healthrelated quality of life (HRQL) assessed by the St George's Respiratory Questionnaire Total Score
(SGRQ-TS), the secondary outcome was daily step count. Linear mixed-effect models were used
to evaluate the effect of intervention at 4, 8 and 12 months. They found that between-group
difference in daily step count was maximal and statistically significant at month 4 (P<.001) but
approached zero in months 8-12. Also, at 12 months, there were no significant between-group
differences in SGRQ-TS or daily step count. Within the intervention group, mean 76.7% (SD
29.5) of 366 days had valid step-count data, which decreased over the months of study (P<.001).
They concluded that an Internet-mediated, pedometer-based PA intervention, although
efficacious at four months, did not maintain improvements in HRQL and daily step counts over
time.
Pharmacological and Nonpharmacological Management of Schizophrenia
Berger et al. (2012) studied adherence to second generation antipsychotic medications
such as aripiprazole, quetiapine, and ziprasidone, as prescribed following hospitalization for
schizophrenia and bipolar disorder. They used a database linking hospital admission records to
health insurance claims and identified 43 patients hospitalized for schizophrenia, and 84 patients
with bipolar disorder between January 1, 2001 and September 30, 2008. During the 6-month
period following hospitalization, patients with schizophrenia received an average of 101 therapydays with the second-generation antipsychotic agent prescribed at discharge. Mean medication
possession ratio (MPR) at 6 months was 55.1% for schizophrenia patients, and 37.3% for
patients with bipolar disorder; roughly 25% of patients switched to another agent over this
period. These findings are indicative of poor adherence to treatment with aripiprazole,
quetiapine, or ziprasidone at hospital discharge.
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Wildgust & Beary (2010) searched the literature to examine the impact of modifiable risk
factors on excess schizophrenia mortality and to what extent these factors can be managed.
Using the search terms schizophrenia and mortality and modifiable (OR reduction OR
intervention), Wildgust and Beary searched Medline, Embrase, and PsycInfo from 1987 to
January 2010 and found 974 articles related to excess mortality in schizophrenia, modifiable risk
factors in the general population, modifiable mortality risk factors in schizophrenia, nonmodifiable mortality risk factors in schizophrenia, review of studies in schizophrenia designed to
reduce mortality, and can one reduce the mortality risk factors in schizophrenia? The literature
revealed the following: (1) patients with schizophrenia have high levels of the top six modifiable
risk factors identified by the World Health Organization: hypertension, smoking, elevated
glycemia, physical inactivity, obesity, and dyslipidemia; (2) a small number of studies showed
successful interventions to improve these risk factors, but prospective long-term studies were not
available to show their impact on mortality; (3) a number of studies supported that premature
deaths in patients with schizophrenia could be due to health disparities in this category of
patients; (4) suboptimal cardiorespiratory fitness and muscle strength were among the strongest
predictors of all-cause mortality in the general population; (5) cigarette smoking was still one of
the largest risk factors for premature all-cause mortality; (6) lifestyle intervention programs
addressing exercise, smoking cessation and compliance with medication were likely to
significantly decrease mortality in schizophrenia; (7) ultimately, decreasing mortality in
schizophrenic patients would inevitably require having people who advocate for them and ensure
that they receive treatments needed, avoiding prejudice, and establish fitness standards in
schizophrenia care.
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Conclusion
The majority of literature reviewed indicates that the mechanisms of COPD and
schizophrenia are well known and the rate of mortality in individuals with schizophrenia is
greater than that of the general population. Individuals with schizophrenia are likely to suffer
multiple co-morbid conditions that could potentially lead to hospitalizations, and COPD is one of
those comorbid conditions. As a matter of facts, one VA study found that schizophrenia nearly
doubled the odds of pulmonary disease (pneumonia and COPD) in the last year of life.
Moreover, a study demonstrated that individuals with schizophrenia and other non-affective
psychosis have significantly lower lung function values, compared with the general population. It
is also documented that individuals with serious mental illnesses (SMIs) such as schizophrenia or
bipolar disorder, have an increased risk for hospitalizations for ambulatory care-sensitive
conditions and rehospitalization for the same or another ACSC within 30 days. Likewise,
patients treated for depression and for schizophrenia while hospitalized are at higher risk for
potentially avoidable 30-day readmissions. An effective model to predict the reduction of 30-day
avoidable readmissions of patients with HF, AMI, PNA, and COPD was developed for VISN 11
of the VA. Nonetheless, there is gap in the literature regarding schizophrenia in general, and
predisposition of schizophrenic South Carolinians in particular, to be readmitted within 30 days
after being treated for AECOPD.

31

THE IMPACT OF SCHIZOPHRENIA
CHAPTER 3
Methodology

Purpose, objectives, and design of project
The purpose of this study was to examine if the coexistence of schizophrenia would
increase 30 day-readmission rates among South Carolinians with COPD. Its two key objectives
were: (1) to determine if schizophrenia is a significant predictor for 30-day COPD readmission
after adjusting for the other covariates (age, gender, anxiety, smoking status, T2DM, GERD and
chronic ischemic heart disease); (2) to suggest lifestyle approaches to manage both COPD and
schizophrenia. The PICO question for the research study was as follows: “In the hospitalized
South Carolinians with COPD (P), how does having schizophrenia (I) compared to not having
schizophrenia (C) influence the 30-day readmission rate (O)?
Since individuals with schizophrenia are likely to suffer multiple comorbid conditions
that could potentially lead to hospitalizations (Olfson, Gerhard, Huang, Crystal, & Stroup, 2015),
this study sought to investigate a possible relationship between the coexistence of COPDschizophrenia and 30-day readmission for COPD in South Carolinians. To better achieve this
goal, a retrospective cohort design was chosen because the study will be done on a preexisting
population. Cohort studies are designed by selecting a group of exposed individuals and a group
of nonexposed individuals and follow them with the aim to compare the incidence of a disease or
the mortality rate from a disease (Gordis, 2014, p. 179). A cohort study is said to be retrospective
when historical data are used, reason why this type of study is also called historical cohort or
nonconcurrent prospective study. In application to the current study, it looked at data related to a
group of South Carolinians hospitalized in the past, from 1996 to 2015. Contrary to classic
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epidemiological study, the 30-day readmission rate of a group of South Carolinians with acute
exacerbation of COPD (AECOPD) and schizophrenia was compared to the one of a different
group of South Carolinians without schizophrenia. Based on the PICO question detailed above,
the dependent variable (DV) or outcome variable was “30-day readmission.” There was one
major independent (factor variable) with two levels:
1.

South Carolinians with underlying schizophrenia, admitted in the hospital for AECOPD.

2. South Carolinians without schizophrenia, admitted in the hospital for AECOPD.
The other covariates (CV) are:
1. Gender (male/female)
2. Age group (< 65 years/≥ 65 years)
3. Anxiety
4. Smoking status
5. T2DM
6. GERD
7. Chronic ischemic heart disease.
Procedure
Following IRBs approval, an Application for Encounter Data and a signed Data Use
Agreement was sent to the South Carolina Revenue and Financial Affairs Office (RFA). This
retrospective study included dates of hospital discharge from January 1, 1996 to September 30,
2015. The following ICD 9 were sent as variables and values to be used for record selection:
491.21: AECOPD/Obstructive chronic bronchitis with exacerbation
491.22: Obstructive chronic bronchitis with acute bronchitis
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Primary and Secondary diagnoses.
RFA was also asked to create a dichotomous schizophrenia variable indicating whether the
patient has any inpatient or outpatient diagnosis of schizophrenia (ICD 9: 295.XX) during the
time frame. Preparatory research performed by the RFA indicated that there were approximately
155,000 discharges that met the inclusion criteria of this study and a baseline readmission
proportion of 0.07. As Figure 1 below from PASS 14 sample size software showed, a
readmission proportion of about 0.09 or greater in schizophrenics would result in ≥ 80% power
to show a statistically significant difference between the two groups using a two-sided alpha of
0.05. Figure 1 did not reflect the increase in power which usually occurs with the addition of
needed covariates to the logistic model. According to Mackinnon (2013), the addition of one or
two good covariates undeniably improves statistical power without complicating a statistical
model.
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Figure 1
Relationship between power and readmission proportion of schizophrenic patients for AECOPD.

Protection of human subjects
Although there was no direct contact with study participants, approval of Southern
Adventist University’s Internal Review Boards (IRBs) was obtained. In the data application, a
patient unique identifier was requested because the outcome variable is “30-day readmission”.
The unique identifier for each patient was also intended to prevent any one, including the
principal investigator of this study, would be able to discover patients’ identity. To ensure
additional confidentiality, only the year and month of initial and subsequent discharges of each
patient were requested, rather than asking for the date. Alternatively, the RFA was asked to
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identify the initial discharge of a given patient, and then give the time in days to any subsequent
discharges.
Description of measures
After receiving the data from the RFA, measurements and calculations were done in three
phases, univariate analysis, bivariate analysis and multivariate analysis. In the univariate analysis
phase, descriptive analysis was completed on each IV and CV. Because of the clustered
readmission, a series of GEE models was used. Bivariate analyses consisted of running a series
of GEE regressions with 30-day readmission as the outcome, entering individual CVs.
Multivariate analyses consisted in performing a series of GEE regressions analyses to determine
the association of schizophrenia and the covariates each with 30-day AECOPD exacerbation
readmission. Covariates chosen were age, gender, smoking status, anxiety, ischemic heart
disease, type 2 diabetes mellitus, gastroesophageal reflux disease (GERD), pulmonary
hypertension. These covariates were chosen based on their association – in the literature- with
hospital readmission of individuals suffering from mental illnesses such as schizophrenia, bipolar
disease and depression. All statistics tests were run in R, then SPSS. In the multiple regression
phase, SPSS displayed the odds ratio and confidence interval to aid in determining the statistical
significance of association found between an independent variable and the outcome variable.
Evaluation plan
The absence of randomization is an undeniable weakness of cohort studies, including this
one. Nonetheless, Figure 1 suggested an association between 30-day readmission and
schizophrenia in patients with AECOPD. Another disadvantage was the inability to establish
causation or generate incidence rate and risk as also seen in case-control studies (PennState,
2017; Lewallen & Courtright, 1998). Similarly, comorbidities and other co-existing psychiatric
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disorders, medication compliance, family support, and the complexity of schizophrenia’s
etiology were real threats to the internal validity of this study. Some advantages included cost
effectiveness, the ease to conduct the study, and the potential to be powerful. Selection and
information biases seen in classic cohort studies were not applicable to this study’s unique
design.
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CHAPTER 4
Results
Univariate Analyses

The data received from the South Carolina Revenue and Financial Affairs Office (RFA)
included 325,780 observations and 70 variables. The following data were excluded: patients
under the age of 15 years, patients with unknown gender, negative span days and admissions
where it was uncertain whether a 30-day readmission occurred, mainly, the September 2015
admissions. The resulting data set was 323,237 observations.
Additional variables were created to run descriptive, binary and regression analyses.
Those variables included schizophrenia, inclusion criteria, exacerbation, acute bronchitis, 30-day
readmission, other mental illnesses, and severity of disease as illustrated by ICU admission.
Bipolar disease, T2DM, and GERD had strong preliminary generalized estimating equation
(GEE) and were included in the analysis. The covariate age was dichotomized in ages < 65, and
≥ 65 years. Because admissions are clustered within patients, a p value was calculated, rather
than running a chi square test. GEE is another way to estimate the parameters of a logistic
regression model. The maximum likelihood estimation (MLE) would be another way. The
difference between GEE and MLE is that GEE is able to take the within subject variance in
consideration, which MLE does not. It does not require to know the variance or covariance
structure in order to model the mean response. The same patient could have been admitted more
than once, and the data do not reflect that.
Table 1 indicates the baseline characteristics of the patients by schizophrenia status. Of
the 323,237 COPD patients for whom data were collected, 3,812 (1.18%) had a diagnosis of
schizophrenia. Of the total sample, 152, 624 (47.22%) were males; 201,692 (62.4%) were age 65
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years or more. Since GEE automatically calculated p values, Table 1 also indicates that age
group significantly predicts schizophrenia status (p < 0.001); but gender does not (p = 0.061).
While initially, it was the intent to collect data related to race, this data was not available. Other
mental illnesses were recorded. Including tobacco and substance abuse which are common in
COPD and schizophrenic patients, there were 122,131 (37.78%) of the total group with mental
health diagnoses. Excluding tobacco use but including other substance abuse diagnoses, there
were 59,999 (18.56%) with mental health diagnoses. There were significantly more comorbid
mental health diagnoses in patients with schizophrenia than in the COPD patients without
schizophrenia, as can be seen in Table 1. Mental illnesses (p < 0.001), anxiety (p = 0.001),
bipolar disorder (p = 0.002), personality disorder (p = 0.028), smoking status (p < 0.001),
admission to ICU (p = 0.002), and T2DM (p <0.001) are the other covariates that significantly
predicted schizophrenia status. There were 36,683 (11.4%) COPD admissions with secondary
diagnosis of anxiety, 5,229 (1.6%) with bipolar disease, 447 (0.1%) with personality disorder,
87,910 (27.2%) with nicotine use, 53,388 (16.5%) admissions or transferred to ICU, and 60,930
(18.8%) with T2DM. Depression, eating disorder, attention deficit disorder, ischemic heart
disease, congestive heart failure, pulmonary hypertension, and GERD were not significant
predictors of schizophrenia status.
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Table 1
Baseline Characteristics by Schizophrenia Status*

Variable
Male Gender

All Admissions
(n=323,237)

Schizophrenic
(n=3,812)

Not
Schizophrenic
(n=319,425)
150,916 (47.2%)

P-value**

152,624
1,708 (44.8%)
0.061
(47.2%)
Age ≥ 65 years
201,692
1,179 (30.9%)
200,513 (62.8%)
<0.001
(62.4%)
Other Mental Illness***
122,131
2,176 (57.1%)
119,955 (37.6%)
<0.001
(37.8%)
Other Mental
59,999
1,049 (27.5%)
58,950 (18.5%)
<0.001
Illness****
(18.6%)
Depression
1816 (0.6%)
36 (0.9%)
1780 (0.6%)
0.952
Anxiety
36683
294 (7.7%)
36689
0.001
(11.4%)
(11.5%)
Eating Disorder
28
2 (0.0%)
26 (0.0%)
0.501
(0.0%)
Attention Deficit
124
2 (0.1%)
122 (0.0%)
0.798
Disorder
(0.04%)
Bipolar Disorder
5229
498 (13.1%)
4731 (1.5%)
0.002
(1.6%)
Personality Disorder
447
31 (0.8%)
416 (0.1%)
0.028
(0.1%)
Smokers
87910
1762 (46.2%)
86148 (27%)
<0.001
(27.2%)
Admitted to ICU
53388
827 (21.7%)
52561 (16.5)
0.002
(16.5%)
Type 2 Diabetes
60930
907 (23.8%)
60023 (18.9%)
<0.001
Mellitus
(18.8%)
Ischemic Heart Disease
576
5 (0.1%)
571 (0.2%)
0.346
(0.1%)
Congestive Heart
1592
12 (0.3%)
1580 (90.5%)
0.205
Failure
(0.5%)
Pulmonary
1228
9 (0.2%)
1219 (0.4%)
0.314
Hypertension
(0.4%)
GERD
56777
583 (15.3%)
56194 (17.6%)
0.368
(17.6%)
*Counts (%) **By simple GEE logistic regression ***Includes tobacco use disorder and other
substance abuse **** Does not include tobacco use disorder, but does include other substance
abuse
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Table 2 indicates the comparison of selected characteristics by readmission status. Of the
total sample of 323,237 patients in this sample, 36,035 (11.15%) were readmitted within 30 days
of discharge. Of the 152,624 (47.2%) males, 17,870 (49.6%) were readmitted, and 22,223
(61.7%) of patients 65 years or older out of 201,692 (62.4%) were readmitted. Of the 122,131
(37.8%) admitted patients with tobacco use disorder and other substance abuse, 14,290 (39.7%)
were readmitted, while 7,853 (21.8%) out of 59,999 (18.6%) of patients without tobacco use but
with other mental illnesses were readmitted. Patients with mental health diagnoses were a
significant proportion of the 30-day readmission sample. Still, gender (p < 0.001), age 65 years
or older (p < 0.001), comorbid mental illnesses (p = 0.006), anxiety (p < 0.001), T2DM (p =
0.002), GERD (p < 0.001) significantly predicted readmission within 30 days after admission for
AECOPD. There were 5,338 (14.8%) out of 36,983 (11.1%) COPD readmissions with secondary
diagnosis of anxiety, 7,264 (20.2%) out of 60,930 (18.8%) with T2DM, and 6,983 (19.4%) from
a total of 56,777 (17.6%) with GERD. Depression, eating disorder, attention deficit disorder,
bipolar disorder, personality disorder, nicotine use, admission in the ICU, ischemic heart disease,
congestive heart failure, and pulmonary hypertension were not significant predictors of 30-day
readmission.
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Table 2
Comparison of Selected Characteristics by Readmission*
Variable
Male Gender
Age≥65 years
Other Mental Illness***

All Admissions
(n=323,237)
152,624
(47.2%)
201,692
(62.4%)
122,131
(37.8%)
59,999
(18.6%)
1,816 (0.6%)
36,983 (11.4%)
28 (0%)
124 (0%)

Readmitted
(n=36,035)
17,870 (49.6%)

Not Readmitted
(n=287,202)
134,754 (46.9%)

22,223 (61.7%)

179,469 (62.5%)

<0.001

14,290 (39.7%)

107,841 (37.5%)

0.006

P-value**
<0.001

Other Mental
7,853 (21.8%)
52,146 (18.2%)
0.006
Illness****
Depression
216 (0.6%)
1,600 (0.6%)
0.795
Anxiety
5,338 (14.8%)
31,645 (11%)
<0.001
Eating Disorder
2 (0%)
26 (0%)
0.861
Attention Deficit
6 (0%)
118 (0%)
0.469
Disorder
Bipolar Disorder
5,229 (1.6%)
663 (1.8%)
4,566 (1.6)
0.128
Personality Disorder
447 (0.1%)
65 (0.2%)
382 (0.1%)
0.416
Smokers
87,910 (27.2%)
9,684 (26.9%)
78,226 (27.2%)
0.815
Admitted to ICU
53,388 (16.5%)
6,232 (17.3%)
47,156 (16.4%)
0.319
Type 2 Diabetes
60,930 (18.8%)
7,264 (20.2%)
53,666 (18.7%)
0.002
Mellitus
Ischemic Heart Disease
576 (0.2%)
61 (0.2%)
515 (0.2%)
0.355
Congestive Heart
1,592 (0.5%)
185 (0.5%)
1,407 (0.5%)
0.781
Failure
Pulmonary
1,228 (0.4%)
142 (0.4%)
1,086 (0.4%)
0.795
Hypertension
GERD
56,777 (17.6%)
6,983 (19.4%)
49,794 (17.3%)
<0.001
*Counts (%), readmitted within 30 days for COPD exacerbation **By simple GEE logistic
regression ***Includes tobacco use disorder and other substance abuse **** Does not include
tobacco use disorder, but does include other substance abuse.
Hypothesis Testing and Bivariate Analyses
The PICO question for this research study is: “In the hospitalized South Carolinians with
COPD (P), how does having schizophrenia (I) compared to not having schizophrenia (C)
influence the 30-day readmission rate (O)? It was hypothesized that South Carolinians with
COPD and schizophrenia were likely to be readmitted more frequently 30 days after being
hospitalized for an AECOPD. Thus, bivariate chi square analysis was done to determine if there

42

THE IMPACT OF SCHIZOPHRENIA
is a difference in readmission rates for those with schizophrenia versus those without. No
significant difference was found (𝜒²(1) = 2.628, p = 0.105) as shown in Table 3 (only consider
the p value in the Test of Model Effects). There were significant differences in readmission
based on:
-

Gender; for males (𝜒²(1) = 37.518, p = 0.000) as seen in Table 4 - Appendix A.

-

Age (𝜒²(1) = 406.220, p = 0.000) as shown in Table 5 - Appendix A.

-

Anxiety (𝜒²(1) = 111.187, p = 0.000) as revealed in Table 6 - Appendix A.

-

T2DM (𝜒²(1) = 23.561, p = 0.014) as illustrated in Table 7 - Appendix A.

-

GERD (𝜒²(1) = 55.594, p = 0.000) as seen in Table 8 - Appendix A.

There was no statistical significant difference in 30-day readmission based on smoking
status (𝜒²(1) = 0.130, p = 0.719) as revealed in Table 9 - Appendix A, and on chronic ischemic
heart disease (𝜒²(1) = 1.928, p = 0.165) as illustrated 10 - Appendix A.
Table 3
Thirty-Day Readmission Based on Schizophrenia Status (Model-based)

Source
(Intercept)
Schizophrenia

Test of model Effects
Type III
Wald Chi-Square
df.
2904.374
1
2.628
1

Dependent Variable: Readmission30b
Model: (Intercept), Schizophrenia

Sig.
0.000
0.105
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Parameter Estimates
95% Wald
Confidence
Interval

95% Wald
Confidence
Interval for
Exp(B)

Hypothesis Test

B

Std
Error

Lower

Upper

Wald
ChiSquare

df

Sig

Exp(B)

Lower

Upper

Intercept

2.069

0.0971

1.878

2.259

453.712

1

0.000

7.915

6.543

9.574

Schizophrenia
=No

0.617

0.0981

0.425

0.809

39.566

1

0.000

1.853

1.529

2.246

Schizophrenia
=Yes

0a

Scale

1

Parameters

1

Multivariate Analysis
Using the GENLIN function in SPSS, the logic link, the Fisher method with full
likelihood, and exchangeable correlation type, exploratory multivariate data analysis was done
using the variables in the data set to create a model for predicting readmission within 30 days for
COPD patients. Because of the categoric nature of the dependent variable, multiple logistic
regression procedures were used. Several models were created. The odds ratio and their
respective 95% confidence intervals were included. Since GEE is a semiparametric method
which relies solely on the data to inform the user, there were no constraints of meeting
assumptions. The first model used eight independent variables analyzed per the robust method
(Table 4). This model resulted in six significant predictors of readmission: Gender (𝜒²(1) =
77.151, p = 0.046); Anxiety (𝜒²(1) = 31.318, p = 0.000); Age (𝜒²(1) = 272.996, p = 0.000);
T2DM (𝜒²(1) = 5.982, p = 0.014); Smoking Status (𝜒²(1) = 4.867, p = 0.027); and GERD (𝜒²(1)
= 14.126, p = 0.000).
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Schizophrenia was slightly below significance level (p = 0.054), chronic ischemic disease
was not significant (p = 0.332)
Table 11
Logistic Regression Output- Robust Method
Tests of Model Effects
Source

Type III
Wald Chi-Square

df

Sig.

405.025

1

0.000

Schizophrenia

3.705

1

0.054

SEX

77.151

1

0.000

Anxiety

31.318

1

0.000

AGRP65

272.996

1

0.000

Chronic Ischemic Heart dz

0.941

1

0.332

T2DM

5.982

1

0.014

Smoking Status

4.867

1

0.027

GERD

14.126

1

0.000

Intercept

Dependent Variable: Readmission30b
Model: (Intercept), Smoking Status, Schizophrenia, SEX2, Anxiety, AGRP65,
Chronic.Ischemic.Heart.dz, T2DM, GERD
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Parameter Estimates
95% Wald
Confidence
Interval

-2.708

Std
Error
0.0162

Schizophrenia =
Yes

.213

.1108

Schizophrenia =
NO

0a

Parameters
Intercept

SEX2 = Male

B

0.120
0

Anxiety = YES

0.198

AGRP65 = Less
than 65 years
AGRP65 = 65
years or older

Lower

Upper

-2.740

-2.676

Wald ChiSquare
27783.892

-0.004

.430

3.705

df

Sig

Exp(B)

Lower

Upper

1

0.000

0.067

0.065

0.069

1

0.054

1.238

0.996

1.538

1.095

1.162

1
0.0150

0.091

0.150

64.558

1

0.000

0.0355

0.129

0.268

31.318

0

-.385

Chronic ischemic
heart dz = NO

0a

T2DM = YES

0.072

T2DM = NO

0a

Smoking status =
YES

0.061

Smoking status =
NO

0a
0.110
a

GERD = NO

0

Scale

1

1

0.000

1.219

1.138

1.307

0.000

0.681

0.650

0.712

0.332

1.228

0.811

1.859

0.014

1.075

1.041

1.139

0.027

1.063

1.007

1.121

0.000

1.117

1.054

1.183

1
0.0233

-0.430

-0.339

272.996

0a
0.205

1.219
1

a

Chronic ischemic
heart dz = YES

GERD =YES

Hypothesis Test

a

SEX2 = Female
Anxiety = NO

95% Wald
Confidence
Interval for
Exp(B)

1
1

0.2116

-0.209

0.620

0.941

1
1

0.0296

0.014

0.130

5.982

1
1

0.0275

0.007

0.115

4.867

1
1

0.0293

0.053

0.168

14.126

1
1

Dependent Variable: Readmission30b
Model (Intercept). Schizophrenia, SEX2, Anxiety, AGRP65, Ischemic Heart dz, T2DM,
Smoking Status, GERD
a
Set to zero because this parameter is redundant.
Interpretation of the strength of association between the predictors and readmission:
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Schizophrenia: Holding the other predictors constant, a patient with schizophrenia
would have an odds ratio of readmission of 1.238, that is a 23.8% increase in the odds
of readmission compared to a person without schizophrenia; with a 95% confidence
interval between 0.996 and 1.538. That is, we are 95% confident that the odds of
readmission for a schizophrenic is between 0.4% lower and 53.8% higher than the
same odds in a non-schizophrenic. The unadjusted schizophrenia odds ratio is not
significantly different from 1 at the 0.05 level.

-

Anxiety: Holding the other predictors constant, a patient with anxiety would have an
odds ratio of readmission of 1.219, that is a 21.9% increase in the odds of readmission
compared to a person without anxiety; with a 95% confidence interval between 1.138
and 1.307, or an increase of odds between 13.8% and 30.7%.).

-

AGRP65: Holding the other predictors constant, a patient less than 65 years old
would have an odds ratio of readmission of 0.319, that is a 31.9% decrease in the
odds of readmission compared to a patient who is at least 65 years old, with a 95%
confidence interval between 0.288 and 0.35, or a decrease of odds between 28.8%
and 35%.).

-

Chronic ischemic heart disease: Holding the other predictors constant, a patient with
chronic ischemic heart disease would have an odds ratio of readmission of 1.228, that
is a 22.8% increase in the odds of readmission compared to a person without chronic
ischemic disease; with a 95% confidence interval between 0.811 and 1.859. In other
words, we are 95% confident that the odds for readmission with a patient with
ischemic heart disease is between 18.9% lower and 85.9% higher than the same odds
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in a patient without ischemic heart disease. The unadjusted ischemic heart disease
odds ratio is not significantly different from 1 at the 0.05 level.
-

T2DM: Holding the other predictors constant, a patient with T2DM would have an
odds ratio of readmission of 1.075, that is a 7.5% increase in the odds of readmission
compared to a person without T2DM, with a 95% confidence interval between 1.014
and 1.139, or an increase of odds between 1.4% and 13.9%.

-

Smoking status: Holding the other predictors constant, a patient who has smoking
disorder would have an odds ratio of readmission of 1.063%, that is a 6.3% increase
in the odds of readmission compared to a person without smoking disorder, with a
95% confidence interval between 1.007 and 1.121, or an increase of odds between
0.7% and 12.1%.).

-

GERD: Holding the other predictors constant, a patient with GERD would have an
odds ratio of readmission of 1.117%, that is 11.7% increase in the odds of
readmission compared to a patient without GERD, with a 95% confidence interval
between 1.054 and 1.183, or an increase of odds between 5.4% and 18.3%.).

Additional comments on the associations:
-

All IVs have a positive relationship with the DV except age less than 65 in other words,
all IVs as coded are risk factors for readmission (odds ratio >1), except for the age group
variable where age less than 65 years is protective.

-

Age is the biggest contributing factor, followed by anxiety, then, gender, GERD, T2DM,
and smoking status.
Comments on the statistical significance of the associations:
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The six significant predictors of readmission: Gender (𝜒²(1) = 77.151, p = 0.046);
Anxiety (𝜒²(1) = 31.318, p = 0.000); Age (𝜒²(1) = 272.996, p = 0.000); T2DM (𝜒²(1) =
5.982, p = 0.014); Smoking Status (𝜒²(1) = 4.867, p = 0.027); and GERD (𝜒²(1) = 14.126,
p = 0.000).
Statement of the regression equation:

-

The regression equation for the robust (GEE) model:
log{P(Y=1) / [1 – P(Y=1)]} = β0 + β1*SEX2 + β2*Anxiety + β3*AGRP65 + β4*T2DM
+ β5*Smoking Status + β6*GERD.
Where P(Y=1) is the probability of readmission, β0 is the intercept, β1 is the coefficient

for SEX2, β2 is the coefficient for Anxiety, β3 is the coefficient for AGRP65, β4 is the coefficient
for T2DM, β5 is the coefficient for Smoking Status, and β6 is the coefficient for GERD.
Log is the natural logarithm.
SEX2 = 1 if the patient is MALE, 0 if FEMALE.
Anxiety = 1 if the patient has an anxiety diagnosis, 0 otherwise.
AGRP65 = 1 if age<65, 0 otherwise.
T2DM = 1 if the patient has a diagnosis of T2DM, 0 otherwise.
Smoking Status = 1 if the patient has a diagnosis of nicotine use disorder, 0 otherwise.
GERD =1 if the patient has a diagnosis of GERD, 0 otherwise.
Alternative regression analyses using a model-based method as opposed to the prior
robust method resulted in one additional variable (schizophrenia) being included as a significant
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predictor of readmission, as illustrated in Table 12 of Appendix B. Smoking Status (𝜒²(1) =
13.750, p = 0.000); Schizophrenia (𝜒²(1) = 9.283, p = 0.002); SEX2 (𝜒²(1) = 44.420, p = 0.000);
Anxiety (𝜒²(1) = 102.552, p = 0.000); Age (𝜒²(1) = 388.340, p = 0.000); T2DM (𝜒²(1) = 17.003,
p = 0.000); and GERD (𝜒²(1) = 42.213, p = 0.000).
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CHAPTER 5
Discussion

Schizophrenia was not found to be a predictor of 30-day readmission after discharge from
an acute exacerbation of chronic obstructive pulmonary disease (p = 0.105, OR=1.172, 95% CI
[0.967, 1.421]. After adjusting for the other covariates (age, gender, anxiety, smoking status,
T2DM, chronic ischemic heart disease, and GERD), schizophrenia was not significantly different
from 1 at the 0.05 level, although the odds ratio was 1.238, increasing the odds of readmission of
a schizophrenic patient by 23.8% compared to a non-schizophrenic patient 95% CI [0.996,
1.538].
Interestingly, GEE logistic regression univariate analysis using the model-based method
showed significance (p = 0.002). Likewise, schizophrenia was a significant predictor for 30-day
readmission at the multivariate level. When all the other predictors were held constant, a patient
with schizophrenia would have an odds ratio of readmission of 1.238, that is a 23.8% increase in
the odds of readmission compared to a patient without schizophrenia, with a 95% confidence
interval between 1.079 and 1.420, or an increase of odds between 7.9% and 42%.). When modelbase GEE regression analysis was done, the matrix assumed that the covariance structure was
accurate. In case of misspecification, the odds ratios and the confidence intervals would be off.
Because the robust p-values are still consistent and unbiased in case of misspecification of the
working correlation matrix, more weight is put in these results compared to the p-values obtained
by the model-based method. Although not quite statistically significant, the results still raise the
possibility that schizophrenia can be a predictor of readmission and further studies using a
prospective approach are recommended.
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Patients treated for depression and schizophrenia while hospitalized were at higher risk
for potentially avoidable 30-day readmissions (Burke, Donzé, & Schnipper, 2013). The
unadjusted ORs of the majority of chronic conditions such as CHF, COPD, asthma, diabetes
mellitus (DM), long and short-term complications, and uncontrolled diabetes were higher for
hospitalizations of people with schizophrenia, versus those without a secondary diagnosis of
schizophrenia (Cahoon, McGinty, Ford & Daumit, 2013). It is thus not surprising that T2DM
was significant predictor for 30-day readmission, and significantly contributed to all regression
models created. Similarly, Jørgensen (2017) found that COPD patients with schizophrenia had a
lower probability of meeting certain process-performance measures for COPD, CHF and
diabetes mellitus; these patients were also more likely to die after an admission for AECOPD.
This scholarly project revealed that mental illnesses are significant predictors for 30-day
readmission; which is consistent with the findings that co-occurring physical and mental
disorders can worsen patient’s course of illness leading to hospital readmission not related to
their psychiatric condition (Šprah, Dernovšek, Wahlbeck, & Haaramo, 2017). Individuals with
serious mental illnesses such as schizophrenia or bipolar disorder were at increased risk for
hospitalization for COPD/asthma exacerbation (IRR: 1.87; 95% CI [1.7, 2.00], Davydow et al.,
2016).
Surprisingly, smoking status was not a significant predictor for 30-day readmission for
AECOPD; yet nicotine use is known as the most predictor for COPD and schizophrenic patients
are usually nicotine-dependent. Cigarette smoking nearly doubled the odds of pneumonia and
COPD in the last year of veterans’ lives (Copeland, Mortensen, Zeber, Pugh, Restrepo, &
Dalack, 2007). Nicotine use and other modifiable cardiovascular risks were the reasons for
excess cardiovascular and respiratory deaths in people with schizophrenia (Olfson, Gerhard,
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Huang, Crystal, & Stroup, 2015). Patients with schizophrenia and other non-affective psychosis
had significantly lower lung function values compared with the general population (Partti et al.,
2015). Copeland et al. (2007) concur with this finding in that VA inpatient decedents with
schizophrenia were at increased risk for pneumonia and COPD, independent of smoking
indicators. Conversely, GERD was a significant predictor. These odds findings can be explained
by the fact that the data set were billing data, among other plausible reasons.
Strengths and Limitations
The strengths of this study include its great power from examining 10 years of data, its
cost effectiveness and the ease to conduct it. Using the robust method for binary regression offset
the GEE limitations caused by the misspecification of the variance-covariance correlation as
mentioned below. The robust method enabled achievement of reliable and efficient estimations
(Khajeh-Kazemi, Golestan, Mohammad, Mahmoudi, Nedjat, & Pakravanc, 2011).
Despite the strengths, there are a number of limitations. Proxy data were used; in fact,
they were billing data, so, it was not possible to have all the desired covariates. There were no
records related to the September 2015 admissions; because it was the last month of data
collection, there was no 30 days in the index admission to see if they were readmitted. The GEE
used for statistical analyses has its own limitations. Parameter estimates could be inefficient in
case the working correlation is misspecified. The consistency of the estimated parameters
depends only on the accurate specification of the mean model; but there is no universally
accepted test for the goodness-of-fit for mean model that extend above binary dependent variable
(Khajeh-Kazemi, Golestan, Mohammad, Mahmoudi, Nedjat, & Pakravanc, 2011). Additionally,
the parameters are sensitive to outliers; if the data is contaminated, the consistency of estimators

THE IMPACT OF SCHIZOPHRENIA

53

is affected (Khajeh-Kazemi et al., 2011). Model selection is not easy to perform in GEE, as
evidenced by the difficulties encountered with this study.
It would have been interesting to see what role racial groups play in the 30-day
readmission; but the data set obtained from the SC RFA did not contain that information. Factors
other than schizophrenia, the complexity of this disease itself, and the fact that some patients had
multiple readmissions were ignored in the analysis. The absence of randomization, the fact that
data were created for insurance purpose, comorbidities and other co-existing psychiatric
disorders, medication compliance, family support or lack thereof, and the complexity of
schizophrenia etiology are some of the threats to the internal validity of this study. Further
exploratory and supplemental studies will be needed to refine this pioneer work.
Implication for Advanced Practice
This scholarly project addressed the important subject of 30-day readmission of
schizophrenic patients following an acute exacerbation of COPD and raised the possibility that
schizophrenia can be a predictor of readmission in South Carolina. There are two compelling
observations that emanate from this scholarly project. First, although COPD is the third leading
cause of death in the US, it does not receive as much attention as other chronic diseases such as
CHF, CAD, MI, or CVA (COPD Foundation (2012). Second, schizophrenic patients are known
to be neglected worldwide (WHO,2016); in 2013, schizophrenia was ranked as the 11th leading
cause of disability worldwide (Global Burden of Disease Study 2013 Collaborators, 2015).
Third, hypertension, nicotine use disorder, hyperglycemia/diabetes, physical inactivity, obesity
and dyslipidemia are the top six modifiable global mortality risk factors, respectively, per the
2009 World Health Organization report on global health risk (Wildgust & Beary, 2010).
Individuals with schizophrenia have high levels of all these risk factors (Wildgust & Beary,
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2010). This scholarly project found that of those factors, smoking status and diabetes mellitus
significantly contributed to the 30-day readmission of schizophrenic patients, (p = 0.027, p =
0.014 respectively). Moreover, literature supports the hypothesis that lifestyle intervention
programs targeting exercise, smoking cessation and compliance with medication are likely to
have significant impact on mortality in schizophrenia (Wildgust & Beary, 2010). It would thus
be appropriate to design comprehensive models of care for schizophrenic patients, models
encompassing lifestyle modification and patient advocacy. In addition to targeting nicotine use
disorder and diabetes, lifestyle modification would also help these patients achieve a state of
overall well-being. Patients advocates will ascertain that the treatments they receive is unbiased
and prejudice-free.
A “need-based” individualized care package with the intent to reduce 30 and 90-day
readmission following an admission for AECOPD was developed by Adamson, Burns, Camp,
Sin, & van Eeden (2016). This model measured mortality rates as well as the length of time until
first readmission for their population. A multidisciplinary COPD Outreach Team (OT) was
created to provide a care package (CP). The OT consisted of a nurse practitioner, a respiratory
therapist, and a physiotherapist. The CP intended to provide patient-specific disease management
based on comprehensive clinical and needs assessment. The ultimate goals of the CP was to: (1)
facilitate continuous care from the hospital to the community; (2) educate patients on their
specific diseases and empower them on the management of those disease; (3) identify and
address individual risk factors; and (4) mobilize appropriate community resources and coordinate
care providers (Adamson et al., 2016). The CP comprised four phases: (1) initial contact, (2)
post-discharge phone-call/contact, (3) home visit; and (4) continued care. Upon admission to the
hospital for AECOPD, patients were enrolled in the program by a member of the OT. Each
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member of the team provided expertise care over the first two to four weeks following patients
discharge The nurse practitioner educated the patients on their disease processes and performed
medication reconciliation. The physiotherapist encouraged mobility while teaching patients safe
mobility techniques to prevent falls. The respiratory therapist assessed breathing, reviewed
breathing techniques and instructed on proper use of inhalers.
Adamson et al. found that although the CP for patients admitted to the hospital for
AECOPD reduced 90-day total mortality and 90-day readmission rate in female patients, it did
not reduce 30 or 90-day readmission rate. For this scholarly project, what could be done
differently would be to add a psychologist and a social worker to the OT. The psychologist
would address the specificities of schizophrenia since it is such a complex disease. The social
worker would address the patients’ social needs, advocate for them and ensuring that they
receive bias-free care. Moreover, the nurse practitioner of the OT will be one who is proficient in
lifestyle medicine interventions. He/she would be tasked to oversee the patients’ care while using
motivational interviewing to help them perceive the need to modify the behaviors (nicotine use,
sedentary life/lack of exercise) that perpetrate their current disease state or make them
susceptible to diseases, and adopt those leading to long term health benefits. In this scholarly
project, bivariate analysis indicated that gender, age, anxiety, T2DM and GERD were significant
predictors of 30-day readmission. In the multivariate analysis, smoking status emerged as
another predictor of 30-day readmission for COPD. While gender and age are not modifiable, the
other covariates are. All members of the OT would need to visit male patients and patients aged
65 at least more often than female and patients less than 65 years old, since these individuals are
more likely to be readmitted. The suggested frequency would be twice a week over the first two
weeks, then weekly thereafter. During these visits, members will pay special attention to
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additional risk factors that could be in their environment and address them when found. The
nurse practitioner (NP) would put emphasis on modifying factors that contributes to anxiety,
T2DM and GERD. To address anxiety, the NP would seek to determine the root of the anxiety
through motivational interviewing (MI). Eventually, the NP could suggest MTHFR mutation
testing because it has been implicated in anxiety (Lynch, 2012). Cognitive behavioral therapy
(CBT) and aerobic exercise produce anxiolytic effects (Gaudlitz, Plag, Dimeo & Ströhle, 2015),
thus can be effectively utilized to relieve anxiety. While finances may be a limiting factor for
certain patients, exercise requires very little investment in good pair of walking shoes. The NP
would keep in mind that patients may have limited functional lung capacity; in which case the
physiotherapist would collaborate with him/her to design the best exercise plan for them. For
T2DM, the NP would visit every three days for the first three weeks, ascertain the patients
understand how, why and how often they are taking the antidiabetic medications prescribed at
discharge. The patients would have to keep taking their medications while the NP teaches them
how to remain normoglycemic by making healthy food choices and exercise regularly, keeping
in mind their functional limitations. The NP may do several other things including, presenting to
his/her patients a very simplified pathophysiology of the disease, shopping with them and
teaching them how to shop in the periphery rather than the center of a grocery store; while
shopping, the NP would also teach the patients how to read food labels. The NP would also teach
the patients how to cook simple but delicious nutrient-dense meals. In case they want to eat out,
advise the patients to call the restaurant ahead of time about the ingredients that they would
rather not have, and request healthy alternatives. After four weeks, the NP would check the
patients’ glycated hemoglobin to measure the effectiveness of his/her interventions. For GERD,
by explaining the side effects of proton pump inhibitors (osteoporosis, nephritis, leaky guts and

THE IMPACT OF SCHIZOPHRENIA

57

certain autoimmune diseases), the NP might be more successful at getting the patient to abide by
the following rules: proper food mastication, avoiding lying down within two or three hours post
prandial, avoiding offenders such as caffeine, alcohol, and spicy foods. Raw potatoes juice is
very effective in neutralizing gastric PH without interfering with gastric parietal cells or the
proton pump mechanism (Pamplona-Roger, 2004, p. 203). Success would be measured by selfreporting. Motivational interviewing and coaching would be of utmost importance in promoting
smoking cessation. The NP would guide each patient in finding what healthy thing they can do
when the urge to smoke arises; going for a short walk or eating an apple for instance. Weekly
discussion on achievement, failures, barriers to making and implementing healthy choices would
be helpful and encouraging for both the patient and NP.
Rather than limiting their interventions to the first two to four months following
discharge, the social worker and psychologist would continue to see the patients as needed; the
nurse practitioner would also be a strong patient advocate and continue to work with the patients
until their treatment goals are met, or the patients terminate the relationship. This
multidisciplinary team approach would address some of the factors that increase the probability
of readmission: premature discharge, inadequate post-discharge support, insufficient follow-up,
therapeutic errors, adverse drug events and other medication related issues, failed handoffs, postprocedural complications, nosocomial infections, pressure ulcers, and patient falls (O’Malley,
Greenwald, Aronson, & Park, L., 2015).
This novel model of care has not been tested, and further studies will be needed to
achieve this. It may not, as in Adamson et al.’s study, reduce the 30-day readmission rate of
schizophrenic patients after hospitalization for AECOPD; but it may reduce their morbidity and
mortality rates. More than anyone else, today’s nurse practitioners are in a position to
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strategically take on and implement proven effective strategies to reduce 30-day readmissions.
They can efficiently head care transition teams. More and more states are giving nurse
practitioners full practice authority, this will unleash their natural propensity to provide care
where and when it is needed, to the fullest of their ability and within the boundary of their
qualifications. Nurse practitioners can also play an important role in destigmatizing
schizophrenia and other mental diseases by their commitment to social justice and respect for
human dignity (ANA, 2015).
Conclusion
This study is a pioneer in seeking a correlation between schizophrenia and COPD
readmission in South Carolina. It has augmented the literature and the hope is that future studies
will build on this ground work with the aim to improve the health of schizophrenic individuals.
Schizophrenic individuals are cognitively impaired, self-negligent, and usually lack family and
social support necessary to remind or encourage them to stay healthy by practicing primary
preventive care. This leads not only to avoidable hospitalizations and readmissions; but also to
premature death. The integration of biblical-based lifestyle practices to their care would aid them
in making better choices, keep them mentally sharp and increase their probability of being
productive citizens. These lifestyle practices would also decrease the economic burden of their
disease by decreasing their antipsychotic use for instance. These medications carry multiple risks
including extrapyramidal symptoms, sudden death, significant cardiac risk (QT prolongation,
torsades de pointes, arrhythmias, hypotension) and diabetes. Medications used to control
extrapyramidal symptoms (Cogentin for instance) are not innocent. Cardiovascular, metabolic,
and infectious diseases are responsible for the 2 to 2.5-fold increased odds of premature death of
schizophrenic patients. In addition to the adoption of the eight principles of CREATION health,
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medical models such as described in this study will allow to continue Christ’s ministry of healing
and caring for the voiceless or the “least of Jesus’ brothers”.
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Appendix A
Bivariate analyses output per the robust method
Table 4
Thirty-Day Readmission Based on Gender

Source
(Intercept)
Gender

Test of model Effects
Type III
Wald Chi-Square
df.
77418.170
1
37.518
1

Dependent Variable: Readmission30b
Model: (Intercept), SEX2

Sig.
0.000
0.000
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Table 5
Thirty-Day Readmission Based on Age

Source
(Intercept)
AGRP65

Test of model Effects
Type III
Wald Chi-Square
df.
65653.280
1
406.220
1

Dependent Variable: Readmission30b
Model: (Intercept), AGRP65

Sig.
0.000
0.000
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Table 6
Thirty-Day Readmission Based on Anxiety

Source
(Intercept)
Anxiety

Test of model Effects
Type III
Wald Chi-Square
df.
46678.109
1
111.187
1

Dependent Variable: Readmission30b
Model: (Intercept), Anxiety

Sig.
0.000
0.000
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Table 7
Thirty-Day Readmission Based on T2DM

Source
(Intercept)
T2DM

Test of model Effects
Type III
Wald Chi-Square
df.
5717.471
1
5.464
1

Dependent Variable: Readmission30b
Model: (Intercept), T2DM

Sig.
0.000
0.000
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Table 8
Thirty-Day Readmission based on GERD

Source
(Intercept)
GERD

Test of model Effects
Type III
Wald Chi-Square
df.
57299.315
1
55.594
1

Dependent Variable: Readmission30b
Model: (Intercept), GERD

Sig.
0.000
0.000
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Table 9
Thirty-Day Readmission Based on Smoking Status

Source
(Intercept)
Smoking Status

Test of model Effects
Type III
Wald Chi-Square
df.
5717.471
1
5.464
1

Dependent Variable: Readmission30b
Model: (Intercept), Smoking Status

Sig.
0.000
0.719
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Table 10
Thirty-Day Readmission Status Based on Chronic Ischemic Heart Disease

Source
(Intercept)
Ischemic.Heart.dz

Test of model Effects
Type III
Wald Chi-Square
df.
5717.471
1
5.464
1

Dependent Variable: Readmission30b
Model: (Intercept), Ischemic.Heart.dz

Sig.
0.000
0.165
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Appendix B
Model-based method and related output
Table 12
Logistic Regression Output- Model-Based Method
Tests of Model Effects
Type III

Source
Intercept

Wald
ChiSquare
991.377

df
1

Sig.
0.000

Smoking.Status
13.750
1
0.000
Schizophrenia
9.283
1
0.002
SEX2
44.420
1
0.000
Anxiety
102.552
1
0.000
AGRP65
388.440
1
0.000
Chronic.Ischemic
2.315
1
0.128
Heart.dz
T2DM
17.003
1
0.000
GERD
42.213
1
0.000
Dependent Variable: Readmission30b
Model: (Intercept), Smoking.Status, Schizophrenia,
SEX2, Anxiety, AGRP65,
Chronic.Ischemic.Heart.dz, T2DM, GERD
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Parameter Estimates
95% Wald
Confidence
Interval

95% Wald
Confidence
Interval for
Exp(B)

Hypothesis Test

Parameters

B

Std
Error

Lower

Upper

Wald ChiSquare

df

Sig

Exp(B)

Lower

Upper

(Intercept)

-2.709

0.0165

-2.742

-2.677

26936.826

1

0.000

0.067

0.064

0.069

Smoking Status =
Yes

0.061

0.0164

0.029

0.093

13.750

1

0.000

1.063

1.029

1.097

Smoking Status =
NO

0a

Schizophrenia =
Yes

0.213

1.079

1.420

Schizophrenia =
No

0a

1.087

1.174

1.174

1.267

0.655

.707

0.943

1.600

1.039

1.139

1.080

1.154

SEX2 = Male

0.122
0

Anxiety = Yes

0.198

AGRP65 = Less
than 65 years
AGRP65 = 65
Years or older

0.076

0.350

9.283

1

0.002

0.0198

0.083

0.161

38.052

1

0.000

0.0196

0.160

0.237

102.552

1

0.000

Chronic Ischemic
Heart dx = NO

0a
0.072

0.0195

-0.423

-0.346

388.440

1

0.000

0

GERD =YES

0.110

GERD = NO

0a

Scale

1

0.681
1

0.1349

-0.059

0.470

2.315

1

0.128

1.228
1

0.0176

0.038

0.107

17.003

1

0.000

a

T2DM = NO

1.219
1

0a
0.205

1.130
1

0

-0.385

1.238
1

a

Chronic Ischemic
Heart dz

T2DM = YES

0.0700

a

SEX2 = Female
Anxiety = No

1

1.075
1

0.0170

0.077

0.144

42.213

1

0.000

1.117
1

Dependent Variable: Readmission30b
Model (Intercept). Schizophrenia, SEX2, Anxiety, AGRP65, Ischemic Heart dz, T2DM,
Smoking Status, GERD.
a
Set to zero because this parameter is redundant.

Interpretation of the strength of association between the predictors and readmission:
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Smoking status: Holding the other predictors constant, a patient who has smoking
disorder would have an odds ratio of readmission of 1.063, that is a 6.3% increase in
the odds of readmission compared to a patient without smoking disorder, with a 95%
confident interval between 1.029 and 1.097, or an increase of odds between 2.9% and
9.7%.).

-

Schizophrenia: Holding the other predictors constant, a patient with schizophrenia
would have an odds ratio of readmission of 1.238, that is a 23.8% increase in the odds
of readmission compared to a patient without schizophrenia, with a 95% confident
interval between 1.079 and 1.420, or an increase of odds between 7.9% and 42%.).

-

SEX2/Gender: Holding the other predictors constant, a male patient would have an
odds ratio of readmission of 113%, that is 13% increase in the odds of readmission,
with a 95% confident interval between 1.087 and 1.174, or an increase of odds
between 8.7% and 17.4%.).

-

Anxiety: Holding the other predictors constant, a patient with anxiety would have an
odds ratio of readmission of 1.219, that is a 21.9% increase in the odds of readmission
compared to a patient without anxiety, with a 95% confident interval between 1.174
and 1.267, or an increase of odds between 17.4% and 26.7%.).

-

AGRP65: Holding the other predictors constant, a patient less than 65 years old
would have an odds ratio of readmission of 0.319, that is a 31.9% reduction in the
odds of readmission, with a 95% confident interval between 0.293 and 0.345 or a
decrease of odds between 29.3% and 34.5%.

-

Chronic ischemic heart disease: Holding the other predictors constant, a patient with
chronic ischemic heart disease would have an odds ratio of readmission of 1.228, that
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is a 22.8% increase in the odds of readmission compared to a person without chronic
ischemic disease; with a 95% confident interval between 0.057 and 1.6, or an increase
of odds between 5.7% and 60%.). Nonetheless, chronic ischemic disease was not
significantly different from 1 at the 0.05 level.
-

T2DM: Holding the other predictors constant, a patient with T2DM would have an
odds ratio of readmission of 1.075, that is a 7.5% increase in the odds of readmission
compared to a patient without T2DM, with a 95% confident interval between 1.039
and 1.113, or an increase of odds between 3.9% and 11.3%.).

-

GERD: Holding the other predictors constant, a patient with GERD would have an
odds ratio of readmission of 1.117%, that is 11.7% increase in the odds of
readmission compared to a patient without GERD, with a 95% confident interval
between 1.080 and 1.154, or an increase of odds between 8% and 15.4%.).

Additional comments on the associations:
-

All IVs have a positive relationship with the DV except age less than 65 in other words,
all IVs as coded are risk factors for readmission (odds ratio >1), except for the age group
variable where age less than 65 years is protective.

-

Age is the biggest contributing factor, followed by schizophrenia, then anxiety, gender,
GERD, T2DM, and smoking status.
Comments on the statistical significance of the associations:
The six significant predictors of readmission: Smoking Status (ꭓ²(1) = 13.750, p = 0.000);
Schizophrenia (ꭓ²(1) = 9.283, p = 0.002); SEX2(ꭓ²(1) = 44.420, p = 0.000); Anxiety
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(ꭓ²(1) = 102.552, p = 0.000); Age (ꭓ²(1) = 388.340, p = 0.000); T2DM (ꭓ²(1) = 17.003, p
= 0.000); and GERD (ꭓ²(1) = 42.213, p = 0.000).
Statement of the regression equation:
-

The regression equation for this model-based model:
log{P(Y=1) / [1 – P(Y=1)]} = β0 + β1*SEX2 + β2*Anxiety + β3*AGRP65 + β4*T2DM
+ β5*Smoking Status + β6*GERD.
Where P(Y=1) is the probability of readmission, β0 is the intercept, β1 is the coefficient

for SEX2, β2 is the coefficient for Anxiety, β3 is the coefficient for AGRP65, β4 is the coefficient
for T2DM, β5 is the coefficient for Smoking Status, and β6 is the coefficient for GERD.
Log is the natural logarithm.
SEX2 = 1 if the patient is MALE, 0 if FEMALE.
Anxiety = 1 if the patient has an anxiety diagnosis, 0 otherwise.
AGRP65 = 1 if age<65, 0 otherwise.
T2DM = 1 if the patient has a diagnosis of T2DM, 0 otherwise.
Smoking Status = 1 if the patient has a diagnosis of nicotine use disorder, 0 otherwise.
GERD =1 if the patient has a diagnosis of GERD, 0 otherwise.
Tables 13-20 illustrate bivariate analyses related to the model-base method; they are similar to
those of the robust output, except for schizophrenia.
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Table 13
Thirty-Day Readmission Based on Schizophrenia Status

Source
(Intercept)
Schizophrenia

Test of model Effects
Type III
Wald Chi-Square
df.
5717.471
1
4.464
1

Dependent Variable: Readmission30b
Model: (Intercept), Schizophrenia

Sig.
0.000
0.019
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Table 14
Thirty-Day Readmission Based on Gender

Source
(Intercept)
Gender

Test of model Effects
Type III
Wald Chi-Square
df.
77418.170
1
37.518
1

Dependent Variable: Readmission30b
Model: (Intercept), SEX2

Sig.
0.000
0.000
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Table 15
Thirty-Day Readmission Based on Age

Source
(Intercept)
AGRP65

Test of model Effects
Type III
Wald Chi-Square
df.
65653.280
1
406.220
1

Dependent Variable: Readmission30b
Model: (Intercept), AGRP65

Sig.
0.000
0.000
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Table 16
Thirty-Day Readmission Based on Anxiety

Source
(Intercept)
Anxiety

Test of model Effects
Type III
Wald Chi-Square
df.
46678.109
1
111.187
1

Dependent Variable: Readmission30b
Model: (Intercept), Anxiety

Sig.
0.000
0.000
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Table 17
Thirty-Day Readmission Based on T2DM

Source
(Intercept)
T2DM

Test of model Effects
Type III
Wald Chi-Square
df.
5717.471
1
5.464
1

Dependent Variable: Readmission30b
Model: (Intercept), T2DM

Sig.
0.000
0.000
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Table 18
Thirty-Day Readmission based on GERD

Source
(Intercept)
GERD

Test of model Effects
Type III
Wald Chi-Square
df.
57299.315
1
55.594
1

Dependent Variable: Readmission30b
Model: (Intercept), GERD

Sig.
0.000
0.000
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Table 19
Thirty-Day Readmission Based on Smoking Status

Source
(Intercept)
Smoking Status

Test of model Effects
Type III
Wald Chi-Square
df.
5717.471
1
5.464
1

Dependent Variable: Readmission30b
Model: (Intercept), Smoking Status

Sig.
0.000
0.719
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Table 20
Thirty-Day Readmission Status Based on Chronic Ischemic Heart Disease

Source
(Intercept)
Ischemic.Heart.dz

Test of model Effects
Type III
Wald Chi-Square
df.
5717.471
1
5.464
1

Dependent Variable: Readmission30b
Model: (Intercept), Ischemic.Heart.dz

Sig.
0.000
0.165

